Publications and Patents
Published Research and Product Portfolio
Publications
Contribution of type III interferons to antiviral immunity: location, location, location (2017) Kotenko SV, Durbin JE; J. Biol. Chem., 592:7295-7303
pubmed.ncbi.nlm.nih.gov: 28289095
Shared and Distinct Functions of Type I and Type III Interferons (2019) Lazear HM, Schoggins JW, Diamond MS; Immunity, 50:907-923
pubmed.ncbi.nlm.nih.gov: 30995506
Phosphatidylserine (PS) is a global immunosuppressive signal in efferocytosis, cancer, and infectious disease (2016) R. B. Birge, S. Boeltz, J. Carlson, S. Kumar, J. Wanderley, D. Calianese, M. l, and P. Agostinos. Barcinski, R. Brekken, J. Hutchins, J. Mercer, A. Schroit, G. Schett, and M. Herrmann (2016). Cell Death and Differentiation 23: 962-974.
PMCID: PMC4987730
Receptor tyrosine kinases, Tyro3, Axl, and Mer, demonstrate distinct and complex regulation of ligand-induced activation. Tsou, W-I, Nguyen, KQ, Calarese, DA, Garforth, SJ, Almo, SC, R. B Birge, and Kotenko SV. (2014) J. Biol. Chem. 289: 25750-25763
PMCID: PMC4162177
Patents
The cornerstone of Targeron’s product portfolio is its intellectual property. Targeron has an exclusive license from Rutgers, The State University of New Jersey for the development and use of the targetable interferon fusion protein technology.
Type I and Type III Interferon Fusion Molecules and Methods for Use Thereof (US 11,292,823; issued 04/05/2022; granted in Japan and pending in Europe) View US 11,292,823
Phosphatidylserine Targeting Fusion Proteins and Methods for Their Use (US 11,352,404; issued 06/07/2022 in US and Japan, pending in Europe) View US 11,352,404
